A Phase 2 interventional study of Bevacizumab and Paclitaxel in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 23 sites in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-23.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies testing bevacizumab in Breast Neoplasms — 9 open to participants now, 10 under way, none of them phase 3. Bevacizumab · Breast Neoplasms.
Among the 131 studies testing bevacizumab in Breast Neoplasms, this one is the 48th largest by enrollment of the 130 interventional ones that give a count, is one of 10 that started in 2009, is one of 89 in phase 2, and was the 79th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →9 of the 131 studies testing bevacizumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18–70 · Women only
Yukinori Ozaki · Sites in Japan
Ages 18+
Tongji Hospital · Sites in China
Ages 18+
Lebanese University · Sites in Lebanon
Ages 18+
Henan Cancer Hospital · Sites in China
Ages 18–70 · Women only
By country, each count listing its studies:
Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 96 · Phase 3 19 · Phase 4 4
First in 2000; this study’s year is marked. 10 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 58 across the 130 interventional studies. Of the 106 that completed or were terminated, 59 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 131 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 28 under way, 13 of them phase 3. Of 193 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 109th largest by enrollment of the 170 interventional ones that give a count, is one of 18 that started in 2009, is one of 65 in phase 2, and was the 47th registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
3 of the studies testing bevacizumab in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05398861Henan Cancer HospitalUtidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer | 2026-12-30 |
| NCT07359404YING FANSacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC | 2026-12-31 |
| NCT07150208Fudan UniversityT-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 131 studies testing bevacizumab in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This single-arm study assessed the efficacy and safety of first-line treatment with Avastin (bevacizumab) in combination with taxane-based chemotherapy (paclitaxel and gemcitabine) in patients with HER-2 negative breast cancer. Patients received Avastin 10 mg/kg iv, paclitaxel 150 mg/m\^2 iv, and gemcitabine 200 mg/m\^2 iv on Day 1 and Day 15 of each 4-week treatment cycle until disease progression, death, or withdrawal of consent.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received bevacizumab 10 mg/kg intravenously (IV), paclitaxel 150 mg/m\^2 IV, and gemcitabine 2000 mg/m\^2 IV on Day 1 and Day 15 of each 4-week cycle until disease progression, unacceptable toxicity, or withdrawal of consent.
Drug: Bevacizumab · Drug: Paclitaxel · Drug: Gemcitabine
Bevacizumab was supplied as a sterile liquid in glass vials.
Also known as: Avastin
Paclitaxel was supplied as a sterile liquid in glass vials.
Also known as: Taxol
Gemcitabine was supplied as a sterile liquid in glass vials.
Also known as: Gemzar
Progression-free Survival
Progression-free survival was defined as the time from enrollment in the study to the first documented disease progression using Response Evaluation Criteria In Solid Tumors (RECIST) or death from any cause, whichever occurred first.
Time frame: Baseline to the end of the study (up to 2 years 10 months)
Percentage of Participants With an Objective Response
An objective response was defined as a complete or partial response determined on 2 consecutive occasions ≥ 4 weeks apart using Response Evaluation Criteria in Solid Tumors (RECIST). Complete response was defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must be \< 10 mm on the short axis. Partial response was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum.
Time frame: Baseline to the end of the study (up to 2 years 10 months)
Duration of the Objective Response
Duration of the objective response is defined as the time from a complete or partial response to disease progression or death due to disease.
Time frame: Baseline to the end of the study (up to 2 years 10 months)
Overall Survival
Overall survival is defined as the time from the first dose of study medication until death.
Time frame: Baseline to the end of the study (up to 2 years 10 months)
| Milestone | Bevacizumab + Paclitaxel + Gemcitabine |
|---|---|
| Started | 90 |
| Received treatment | 83 |
| Completed | 0 |
| Not completed | 90 |
| Withdrew: Death | 3 |
| Withdrew: Disease progression | 30 |
| Withdrew: Toxicity | 12 |
| Withdrew: Patient decision | 7 |
| Withdrew: Investigator discretion | 29 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Subject not treated | 7 |
Progression-free survival was defined as the time from enrollment in the study to the first documented disease progression using Response Evaluation Criteria In Solid Tumors (RECIST) or death from any cause, whichever occurred first.
| Months | Bevacizumab + Paclitaxel + Gemcitabine |
|---|---|
| Progression-free Survival | 11.51 (9.01 to 17.59) |
An objective response was defined as a complete or partial response determined on 2 consecutive occasions ≥ 4 weeks apart using Response Evaluation Criteria in Solid Tumors (RECIST). Complete response was defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must be \< 10 mm on the short axis. Partial response was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum.
| Percentage of participants | Bevacizumab + Paclitaxel + Gemcitabine |
|---|---|
| Percentage of Participants With an Objective Response | 72.37 (60.91 to 82.01) |
Duration of the objective response is defined as the time from a complete or partial response to disease progression or death due to disease.
| Months | Bevacizumab + Paclitaxel + Gemcitabine |
|---|---|
| Duration of the Objective Response | 12.39 (7.63 to 15.16) |
Overall survival is defined as the time from the first dose of study medication until death.
| Months | Bevacizumab + Paclitaxel + Gemcitabine |
|---|---|
| Overall Survival | 27.39 (21.86 to NA) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bevacizumab + Paclitaxel + Gemcitabine | — | 21/82 (25.6%) | 82/82 (100%) |
| Event | Bevacizumab + Paclitaxel + Gemcitabine |
|---|---|
| FeverInfections and infestations | 4/82 |
| Catheter site infectionInfections and infestations | 2/82 |
| AnorexiaGastrointestinal disorders | 1/82 |
| Gastrointestinal perforationGastrointestinal disorders | 1/82 |
| VomitingGastrointestinal disorders | 1/82 |
| DehydrationGastrointestinal disorders | 1/82 |
| DiarrhoeaGastrointestinal disorders | 1/82 |
| Febrile neutropeniaInfections and infestations | 1/82 |
| InfectionInfections and infestations | 1/82 |
| Cardiac ischemia/infarctionCardiac disorders | 1/82 |
| Event | Bevacizumab + Paclitaxel + Gemcitabine |
|---|---|
| Neuropathy: sensoryNervous system disorders | 62/82 |
| FatigueGeneral disorders | 54/82 |
| Haemorrhage, pulmonary/upper respiratory noseVascular disorders | 30/82 |
| Pain oral-gumsGeneral disorders | 28/82 |
| Hair loss/alopecia (scalp or body)Skin and subcutaneous tissue disorders | 28/82 |
| NauseaGastrointestinal disorders | 27/82 |
| Neutrophils lowBlood and lymphatic system disorders | 26/82 |
| VomitingGastrointestinal disorders | 25/82 |
| DiarrhoeaGastrointestinal disorders | 20/82 |
| Rash/desquamationSkin and subcutaneous tissue disorders | 20/82 |
Intent-to-treat population: All participants enrolled in the study.
| Age, Continuous(years) | Bevacizumab + Paclitaxel + Gemcitabine |
|---|---|
| Mean | 52.20 ± 12.48 |
| Sex: Female, Male(Participants) | Bevacizumab + Paclitaxel + Gemcitabine |
|---|---|
| Female | 89 |
| Male | 1 |
The record gives a start of Jan 2009, a primary completion of Dec 2011 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bevacizumab · Paclitaxel · Gemcitabine